bioMerieux (BIM) AI Stock Analysis

• Market Cap: €14.04B
• Dividend Yield: 0.66%
• Average Volume (3M): 107.77K
• Price to Earnings (P/E): 32.4
• Beta (1Y): 0.70
• Revenue Growth: 8.31%
• EPS Growth: 21.00%
• Country: FR
• Employees: 14,147
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 1.84
• Shares Outstanding: 118,361,220
• 10 Day Avg. Volume: 98,881
• 30 Day Avg. Volume: 107,774
• PEG Ratio: 6.08
• Price to Book (P/B): 3.23
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 42.18
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €131.00
• Price Target Upside: 10.18% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 70 Outperform
• Price Target: ―

bioMerieux exhibits strong financial performance with consistent growth and stability, which is the primary driver of its stock score. Technical indicators suggest a lack of strong momentum, and the stock's valuation appears high relative to peers, which slightly dampens the overall attractiveness. With no new earnings call or corporate events data, these factors do not influence the score.

Positive Factors

Guidance Increase

Full-year guidance was uplifted from 6-8% to 8-10% organic sales growth.

Organic Growth

Organic growth for the quarter was 10.3%, surpassing the consensus expectation of 8.4%.

Product Launches

New product launches like SPOTFIRE, VITEK, and VIDAS approvals are driving in-market traction.

Negative Factors

Installed Base Growth

BIOFIRE installed base growth slowdown may be debated.

Product Segment Performance

Immunoassays are still weighed down by the decrease in procalcitonin tests.

bioMerieux Business Overview & Revenue Model

Company Description

bioMérieux S.A. is a French multinational biotechnology company specializing in the field of in vitro diagnostics. Founded in 1963, the company is part of the Institut Mérieux group and is headquartered in Marcy-l'Étoile, France. bioMérieux designs, develops, and produces diagnostic solutions (systems, reagents, and software) for clinical and industrial applications. Its core products and services include diagnostics for infectious diseases, cancer screening, and cardiovascular emergencies, as well as solutions for ensuring the quality and safety of food and environmental products.

How the Company Makes Money

bioMérieux generates revenue through the sale of its diagnostic systems, reagents, and related software. The company's primary revenue streams include clinical diagnostics, which accounts for a significant portion of its earnings, targeting healthcare facilities, laboratories, and hospitals. Another revenue stream is industrial applications, where bioMérieux provides products for food safety, quality control, and environmental monitoring. The company also engages in partnerships and collaborations with research institutions and other healthcare entities to enhance its diagnostic offerings and expand its market reach. Revenue is driven by the continuous need for diagnostic testing solutions in both clinical and industrial settings, bolstered by the company's global presence and extensive distribution network.

bioMerieux Financial Statement Overview

Summary

bioMerieux is in a strong financial position with consistent revenue and profit growth, solid margins, and effective cash flow management. The balance sheet reflects low leverage and robust equity, indicating financial stability. However, there is room for improvement in return on equity.

Income Statement

bioMerieux has demonstrated strong and consistent revenue growth, with a notable increase of approximately 8.3% from 2023 to 2024. The gross profit margin stands at 55.7%, reflecting effective cost management. The net profit margin is 10.9%, which is solid for the industry. EBIT and EBITDA margins are healthy at 14.8% and 22.5%, respectively, indicating robust operational efficiency.

Balance Sheet

The company exhibits a strong equity base with an equity ratio of 72.9%, indicating financial stability. The debt-to-equity ratio is low at 0.12, suggesting prudent leverage management. The return on equity is 10.3%, which is respectable, though there is room for improvement in generating higher returns on equity.

Cash Flow

bioMerieux's free cash flow has seen significant growth, increasing from €107.1 million in 2023 to €321.5 million in 2024. The operating cash flow to net income ratio is robust at 1.54, showing strong cash conversion from earnings. The free cash flow to net income ratio is 0.74, indicating effective cash generation relative to net income.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
3.98B	3.67B	3.59B	3.38B	3.12B
	Gross Profit
2.22B	2.06B	1.96B	1.97B	1.74B
	EBIT
588.80M	439.10M	559.80M	768.00M	551.20M
	EBITDA
897.50M	827.60M	811.90M	977.80M	747.70M
	Net Income Common Stockholders
432.20M	357.60M	452.40M	601.10M	404.40M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
449.80M	352.40M	552.60M	803.50M	389.20M
	Total Assets
5.77B	5.26B	5.19B	4.61B	3.93B
	Total Debt
490.70M	518.80M	505.40M	462.50M	481.30M
	Net Debt
40.90M	166.40M	-47.20M	-341.00M	92.10M
	Total Liabilities
1.56B	1.51B	1.54B	1.44B	1.45B
	Stockholders Equity
4.20B	3.75B	3.60B	3.11B	2.43B
Cash Flow		Free Cash Flow
321.50M	107.10M	188.40M	534.60M	305.30M
	Operating Cash Flow
667.30M	445.40M	475.10M	824.70M	582.80M
	Investing Cash Flow
-359.80M	-488.80M	-528.10M	-307.30M	-266.00M
	Financing Cash Flow
-212.60M	-122.30M	-244.20M	-140.60M	-175.40M

bioMerieux Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 118.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:BIM, the sentiment is Positive. The current price of 118.9 is above the 20-day moving average (MA) of 118.89, above the 50-day MA of 116.89, and above the 200-day MA of 109.71, indicating a bullish trend. The MACD of 0.90 indicates Positive momentum. The RSI at 50.63 is Neutral, neither overbought nor oversold. The STOCH value of 26.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:BIM.

bioMerieux Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ERF	74 Outperform	€11.05B	28.44	9.66%	0.99%	6.70%	32.29%
SAN	71 Outperform	$100.99B	18.64	7.34%	4.11%	-4.62%	2.88%
BIM	70 Outperform	€14.04B	32.41	10.86%	0.66%	8.31%	21.00%
ALERS	67 Neutral	€255.14M	63.93	2.27%	―	19.15%	-20.71%
DIM	64 Neutral	€19.18B	93.85	5.24%	0.35%	5.21%	-23.23%
Sector *	54 Neutral	$5.24B	3.26	-44.35%	6.48%	16.78%	-0.10%

bioMerieux Corporate Events

bioMérieux’s VITEK® COMPACT PRO Gains FDA Approval to Combat Antibiotic Resistance

bioMérieux has received 510(k) authorization from the FDA for its VITEK® COMPACT PRO system, designed to enhance the identification of microorganisms and antibiograms in both clinical and industrial settings. This system aims to address the growing challenge of antibiotic resistance by providing rapid, accurate diagnostics, improving laboratory efficiency, and promoting the proper use of antibiotics. The VITEK® COMPACT PRO is set to launch globally in 2025, offering advanced ergonomics and automation to small and medium-sized laboratories, thus strengthening bioMérieux’s position as a leader in microbiology innovation.